Degenerative Disc Disease Clinical Trial
— OASISOfficial title:
OsteoAdapt SP Feasibility Study A Prospective, Blinded, Controlled, Dose-Randomized Clinical Investigation of OsteoAdapt SP in Transforaminal Lumbar Interbody Fusion in Treatment of Symptomatic Degenerative Disease of The Lumbosacral Spine
The purpose of this clinical study is to assess the safety and effectiveness of the OsteoAdapt SP as a replacement for the autograft standard of care bone graft within the interbody cage, as well as identify the OsteoAdapt SP dose to be investigated in a future pivotal study.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 2026 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Male or Female age 18-80 (inclusive) at time of signing informed consent and skeletally mature (as determined by physician's assessment of AP lumbar Xray utilizing the Risser Classification method of the iliac crest growth plates) (See addendum 1 for a definitive reference on skeletal age); - Subject is planning to undergo a unilateral, single-level, single interbody cage, TLIF procedure (from L2-S1 with posterior supplemental fixation) with a primary diagnosis of symptomatic lumbar degeneration including back and/or radicular pain with or without foraminal or recess stenosis confirmed by patient history, physical examinations, and radiographic imaging (xray, CT, MRI) with no more than Grade 2 Spondylolisthesis with one or more of the following factors: 1. Instability as defined by >/-3mm translation or >/-5° angulation; 2. Osteophyte formation of facet joints or vertebral endplates; 3. Decreased disc height, on average by >2mm, but dependent upon the spinal level; 4. Scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule; 5. Herniated nucleus pulposus; facet joint degeneration/changes; and/or 6. Vacuum phenomenon. - Preoperative ODI score =40 at pre-op/baseline; - Preoperative back and/or leg pain score of =4 (out of 10); - Failed =6 months non-operative/conservative treatment (e.g., physical therapy, bracing, traction, medication, TENS, and/or spinal injections; - Is willing and able to be present for routine follow up visits, comply with postoperative management program, and is able to understand and sign the informed consent form. Exclusion Criteria: - Patient requires spinal fusion surgical procedure (TLIF) at more than one level (non-fusion surgery at the non-index levels, including discectomy and/or single level foraminotomy or laminectomy, is allowed) - Prior spinal fusion surgical procedure at the involved or adjacent spinal levels, or non-fusion stabilizing surgeries, e.g., interlaminar devices, dynamic stabilization, or disc replacements. (Prior non-fusion surgery at the target levels, including discectomy and/or single level foraminotomy or laminectomy, is allowed.) - Greater than Grade 2 Spondylolisthesis; - Planned use of an internal or external bone growth stimulator; - Osteoporosis to a degree that spinal instrumentation is contraindicated or a history of a traumatic vertebral fracture. All patients complete SCORE/MORE to assess the need for DEXA scan. If DEXA is required, patients with a T score </- 2.5 will be excluded. A prior DEXA can be used if performed within 9 months pre-op; - Morbidly obese, as defined by a Body Mass Index (BMI) >40; - Overt or active bacterial infection, either local or systemic; - The subject uses, or has used within 30 days of surgery, tobacco or nicotine or is prescribed steroids such as cortisone; (subjects will undergo a nicotine test during screening procedures utilizing a standard commercial cotinine urine dip test; Example: Easy@Home Nicotine Cotinine Urine Panel Dip Test Strips Kit- Sensitive (healthcare-manager.com) - Comorbidities precluding subject from being a surgical candidate; - Systemic disease including Lupus disease, Reiter's disease, Rheumatoid disease, AIDS, HIV, hepatitis, or autoimmune disease that requires immunosuppressive therapy, including biologics, for systemic inflammation. - History of malignancy, radiotherapy, or chemotherapy for any malignancy within the last 5 years. History of malignancy may include multiple exostoses syndrome ((also known as multiple osteochondromas syndrome), an inherited condition associated with bumps of cartilage on the bones, has been associated with an increased risk of chondrosarcoma); individuals who have undergone any transplant surgery and are on immunosuppressant therapy. - Has history of any endocrine or metabolic disorder known to affect osteogenesis (e.g.: Paget's disease, renal osteodystrophy, Ehler-Danlos syndrome, or osteogenesis imperfecta); - Insulin dependent diabetes; - History of exposure to any recombinant proteins or peptides used for bone formation (i.e., Infuse Bone Graft, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft); - Hypersensitivity or allergy to any components of the study treatments including, but not limited to, bone morphogenetic proteins (BMPs); tricalcium phosphate (TCP); PLGA polymer; and/or instrumentation materials (titanium, titanium alloy, PEEK). - History of any allergy resulting in anaphylaxis; - Is a prisoner; - Is mentally incompetent. If questionable, obtain psychiatric consult; - History of substance abuse (substance abuse defined by DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders) code. Criteria for substance abuse defined in Addendum 2. - Involved in litigation for spine injury or worker's compensation case; - Treatment with an investigational therapy (drug, device, and/or biologic) within 120 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment; prior or planned use of rhBMP-2. - Pregnant (or interested in becoming pregnant in the next 24 months) or nursing. - Any condition that would interfere with the subject's ability to comply with study instructions or prohibit MRI/CT/Radiographic assessments that might confound the interpretation of the study or put the subject at risk. - Patients with any positive pregnancy test. Tests will be administered at the surgical center prior to surgery. - Patient currently taking any drug known to interfere with bone/soft tissue healing. See "Medication Protocol" section of the Investigator's Brochure. - Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study. requirements. |
Country | Name | City | State |
---|---|---|---|
Australia | International Spine Centre | Norwood | South Australia |
Lead Sponsor | Collaborator |
---|---|
Theradaptive, Inc |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Subjects requiring Secondary Surgical Interventions within 24 months post-op. | No secondary surgical interventions, due to fusion failure or non- union, including reoperation, supplemental fixation, removal, or revision of the Investigational Device within the study follow up timeframe of 24 months. | up to 24 months post op | |
Primary | Neurological Status assessed via Motor, Sensory, and Reflex physical exams with outcome measures of "normal", "abnormal" or "unknown". Success defined as maintenance or improvement compared to baseline assessment. | • Maintenance or improvement in neurological status affected by the index level at 24 months post-op as compared to baseline measures, as adjudicated by the Medical Monitor. | Baseline compared to 24 months post op | |
Primary | Oswestry Disability Index - Measured on a scale of 0-100 points, 0 being least physically impaired for day to day activities and 100 being extremely difficult or impossible to perform day to day activities. | • Oswestry Disability Index will be compared at 24 months post-op to baseline measures based on a scale of 0-100 points (0 = not physically impaired for day to day activities; 100= severe impairment of day to day activities) Adjacent level progression of pathology will be assessed for any failures of this criteria and adjudicated by the Medical Monitor. | Baseline compared to 24 months post op | |
Primary | Numeric Pain Rating Scale - Pain scale measured on a scale from 0 to 10 (0=no pain; 10 = pain as bad as it can be) compared at 24 months post op to baseline assessment. | • Assessment of the Numeric Pain Rating Scale (NPRS) for back and/or leg pain and defined on a scale of 0 to 10 (0 =no pain; 10 = pain as bad as it can be) Pain scores will be compared at 24 months to baseline values. Adjacent level progression of pathology will be assessed for any failures of this criteria and adjudicated by the Medical Monitor. | Baseline compared to 24 months post op | |
Primary | Radiographic Fusion Assessment - assessed by CT at 12- and 24-months post op as bridging bone from endplate to endplate. | • Radiographic fusion as defined below within 24 months post-op:
Presence of Bridging Bone (CT) in at least one of the following locations: Interbody space; or anterior, lateral, or posterior to interbody fusion device. Bridging bone is defined as continuous evidence of bridging bone, whether it be a thin line, or a thicker column of bone; AND No evidence of motion as defined by less than 3mm translational motion and less than 5° in angular motion at each treated level. No radiological evidence of bridging bone in adjacent levels. |
Assessed at 24 months post op | |
Secondary | PROMIS short form, validated, quality of life questionnaire to assess subjects overall mental and general health through a series of 12 questions regarding depression, anxiety, and general health. | • Assess the subject's health related overall quality of life through the PROMIS Short Form Questionnaire. | 24 months post op | |
Secondary | Assessment for Immunogenic effects (e.g., anti BMP-2) caused by rhBMP2 antibodies as detected in subject's blood serum through antibody assays. | Assessment for Immunogenic effects (e.g., anti BMP-2) through BMP2 antibody and neutralizing antibody assays. | Pre-op to 24 months (if applicable) | |
Secondary | Disc height assessment at the operative level as determined by plain Xray radiographs at each study timepoint. | Disc height assessment at the operative level through radiographic analysis | Pre-op, 6 weeks, 3 months, 6 months, 12 months, 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Active, not recruiting |
NCT05114135 -
TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study)
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Withdrawn |
NCT03223701 -
Efficacy of Using Solum IV and BMC With GFC in TLIF
|
Phase 4 | |
Completed |
NCT04057235 -
Retrospective Review of Integrity Implants FlareHawk® for Lumbar Fusion
|
||
Not yet recruiting |
NCT06000319 -
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
|
||
Active, not recruiting |
NCT02969616 -
Trinity Elite in Lumbar Fusion
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT02104167 -
Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating
|
||
Completed |
NCT00996073 -
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
|
Phase 2 | |
Completed |
NCT00965380 -
Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)
|
||
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Completed |
NCT00758719 -
Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System
|
||
Completed |
NCT00165893 -
Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease
|
Phase 4 | |
Terminated |
NCT01494493 -
Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
|
N/A | |
Recruiting |
NCT04727385 -
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease
|
N/A | |
Completed |
NCT04849429 -
Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain
|
Phase 1 | |
Recruiting |
NCT04469387 -
Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion
|
N/A | |
Recruiting |
NCT04056520 -
Clinical and Radiological Outcomes of Posterior Cervical Fusion With Medtronic Infinity Occipitocervical-Upper Thoracic (OCT) System
|
||
Completed |
NCT04119466 -
Stabilizing Training in Degenerative Disc Disease
|
N/A |